[Study on the effect of continuous administration of IL-1ra in BXSB mice].
OBJECTIVE
To explore the consequences of IL-1 blocking in BXSB mice which is an experimental model for human SLE.


METHODS
rh IL-1ra was expressed in E. coli and injected in BXSB mice. 13 of 4.5 month-age male BXSB mice were divided into two groups, one group was injected rh IL-1ra 10 times (twice a week) at dose of 400 micrograms per mouse each time, another group was injected PBS at the same time as control. We monitored serum ANA and proteinuria weekly, and detected IgG, C3 deposition and IL-6 expression in kidneys at 40th day.


RESULTS
The results showed that the increased level of serum ANA and proteinuria in treatment group were not higher than in control group, the IgG, C3 deposition and IL-6 expression in kidneys and IL-6 activity in serum of the treaed group were lower than the control group, whereas no difference of GPT level in the two groups.


CONCLUSIONS
IL-1 might play a pathogenic role in BXSB mice. Blocking or reducing IL-1 secretion would be of beneficial to the treatment of SLE.
Yang
G
G
PUMC Hospital, Beijing.
Di
C
C
Ma
D
D
Jiang
X
X
Li
S
S
D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism; D008297:Male; D051379:Mice; D011507:Proteinuria / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012795:Sialoglycoproteins / Q000008:administration & dosage / Q000494:pharmacology*
D000974:Antibodies, Antinuclear; C507763:IL1RN protein, human; C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins